Opus Genetics receives FDA clearance to advance RDH12-LCA gene therapy into clinical development
Opus Genetics, a clinical-stage biopharmaceutical company, has recently announced that the U.S Food and Drug Administration has cleared its Investigational New Drug application for OPGx-RDH12. OPGx-RDH12 is an investigational gene therapy in development for the treatment of RDH12-associated Leber Congenital Amaurosis (LCA).